Proceedings of the 48th annual pancreas club meeting.

The 48th annual Pancreas Club meeting was held on May 2 and 3, 2014, at the Westin Lombard in Lombard, IL. Two hundred sixty attendees included pancreatologists from 17 countries. Two hundred eleven abstracts were submitted; from these, a record number (64) oral presentations and 136 posters were selected. Table 1 documents oral abstract titles with institutional affiliation. Full abstracts for all oral presentations and posters are available at the Pancreas Club website, https://pancreasclub.com . Representative abstracts from each of the eight sessions are summarized below. Table 1 Oral papers presented at the 48th Annual Pancreas Club meeting Number Title Institution Scientific session 1  Topic: Borderline resectable pancreatic cancer   1 Diagnostic laparoscopy to detect occult metastatic disease prior to neoadjuvant chemoradiation in borderline resectable pancreatic ductal adenocarcinoma Cleveland Clinic Foundation   2 Risk of venous thromboembolism during neoadjuvant therapy for resectable and borderline resectable (BLR) pancreatic adenocarcinoma (PC) Medical College of Wisconsin   3 Impact of surgical resection after chemoradiotherapy for locally advanced unresectable pancreatic ductal adenocarcinoma Mie University (Japan)  Topic: Neoadjuvant chemotherapy/radiation therapy   4 A comprehensive assessment of neoadjuvant therapy for pancreatic adenocarcinoma: results from the National Cancer Database (NCDB) University of Pennsylvania   5 does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? MD Anderson Cancer Center   6 Neoadjuvant chemoradiation versus neoadjuvant chemotherapy prior to pancreaticoduodenectomy for pancreatic cancer Roswell Park Cancer Institute   7 Changes in body composition during preoperative therapy for resectable pancreatic cancer: do they matter? MD Anderson Cancer Center   8 Prospective randomized controlled study comparing outcome between standard resection and an extended resection that included dissection of the nerve plexus and various lymph nodes in patients with pancreatic head cancer Seoul National University   9 Microscopic residual tumor after pancreaticoduodenectomy for cancer. Preliminary results of a multicentric university of Rome prospective randomized trial University of Rome Scientific session II  Topic: Minimally invasive techniques/screening for cancer   10 Minimally invasive pancreatoduodenectomy: is the learning curve surmountable? Indiana University   11 Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Mayo Clinic   12 Preliminary results of a swedish, mr based, screening program for individuals at risk for pancreas cancer Karolinska Institute (Sweden)   13 Early detection of pancreatic intraepithelial neoplasia using non-invasive imaging to localize and grade protease activity University of California San Francisco Scientific session III: translational studies   14 Role of CYB5A in pancreatic cancer: correlation with clinical outcome and functional characterization in the modulation of autophagy and oncogenic phenotypes University of Pisa (Italy)   15 CA 19-9 response to neoadjuvant therapy predicts outcome in pancreatic adenocarcinoma University of Pittsburgh   16 Detection of clinically relevant genetic alterations in fine needle aspirates of pancreatic cancer is possible using next-generation sequencing Johns Hopkins University   17 New platforms for PDAC preclinical studies: 3D tissue-engineered models based on primary cancer cells and synthetic scaffolds University of Pisa (Italy)   18 Bioluminescent orthotopic pancreatic-ductal-adenocarcinoma (PDAC) mouse models derived from primary PDAC cells as a platform for therapeutic discovery University of Pisa (Italy)   19 Counteracting cancer cell survival strategy: sensitization of pancreatic cancer cells to trail induced cell death by jak2/stat3 pathway inhibition by preventing death receptor down regulation University of Minnesota Scientific session IV  Topic: Pancreatitis   20 Total pancreatectomy with islet autotransplantation for chronic pancreatitis: the price patients pay for improvements in quality of life Medical University of South Carolina   21 Cost-effectiveness of total pancreatectomy with islet cell autotransplantation for the treatment of small duct chronic pancreatitis University of Cincinnati   22 High readmission rates following surgery for chronic pancreatitis University of Cincinnati   23 Pancreaticoduodenectomy for chronic pancreatitis: a long-term follow-up Mayo Clinic   24 Risk of recurrent pancreatitis and progression to chronic pancreatitis after acute pancreatitis Academic Medical Center, Amsterdam (Netherlands)   25 Severe acute pancreatitis: using a multidisciplinary percutaneous drainage protocol the main predictor of hospital length of stay is amylase or bacteria in the percutaneous aspirate St. Luke's Health Care System Boise, ID  Topic: Neuroendocrine tumors   26 Surgical resection provides a significant overall survival benefit for patients with small pancreatic neuroendocrine tumors University of Chicago   27 Risk of malignancy in resected nonfunctioning pancreatic neuroendocrine tumors Mayo Clinic Rochester, MN   28 An investigation of the utility of ki-67 expression in pancreatic neuroendocrine tumour fine needle aspiration samples Glasgow Royal Infirmary (Scotland)   29 The gastrinoma triangle revisited: duodenal wall gastrinoma and pancreatic gastrinoma locations predict biological behavior and longevity Loyola University Chicago, IL   30 Patterns of practice and survival among patients with non-metastatic pancreatic neuroendocrine tumors under 2 cm Mercy Medical Center Des Moines, IA Scientific session V: IPMN   31 Re-classification of combined-type IPMNS allows for a better definition of two disease entities Massachusetts General Hospital   32 Clinical validation of new international consensus guidelines for the resection of branch duct type intraductal papillary mucinous neoplasms (BD-IPMN) Seoul National Medical University   33 Intraductal papillary mucinous neoplasm of the pancreas, one manifestation of a more systemic disease? Indiana University   34 The biology of small IPMN cancers (<20 mm invasive component): a multi-institutional analysis Thomas Jefferson University   35 A national perspective of invasive intraductal papillary mucinous neoplasm (IPMN) University of Pennsylvania   36 Characterization of pancreatic stromal cells isolated from pancreatitis and pancreatic adenocarcinoma surgical specimens University of Florida   37 Current indications for surgery of IPMNs may overlook some patients with cancer: recommendations for change University of California Los Angeles   38 Main pancreatic duct size and risk of malignancy in intraductal papillary mucinous neoplasm Johns Hopkins University   39 Does EUS improve outcome in surveillance of non-resected presumed branch-duct intraductal papillary mucinous neoplasms? Yale-New Haven Hospital   40 Resected pancreatic adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns Johns Hopkins University   41 The indolent nature of pulmonary metastases from pancreatic cancer University of Pittsburgh Scientific session VI  Topic: Cancer Basic   42 Pancreatic stellate cell secreted IL-6 mediates stat3 dependent cance cell invasion Vanderbilt University   43 Neutrophil extracellular traps (NETS) are upregulated in pancreatic cancer as a result of authophagy and contribute to hypercoagulability University of Pittsburgh   44 Isolation and characterization of DCLK1+ tumor cells of pancreatic adenocarcinoma patients University of Oklahoma   45 Sequence alterations in the WEE1 non - coding region is a facilitator and marker for pancreatic tumorigenesis Thomas Jefferson University   46 Chemotherapy resistant pancreatic cancer tumor - associated fibroblasts are protumorigenic University of California   47 PTK6 increases apoptosis with gemcitabine treatment in pancreatic cancer cells by enhancing DNA damage Michigan State University Scientific session VII  Topic: Early complications after pancreaticoduodenectomy/drains and fistulas   48 The value of drains as a fistula mitigation strategy for pancreatoduodenectomy: something for everyone? results of a randomized prospective multi-institutional study University of Pennsylvania   49 A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage Baylor College of Medicine   50 Risk-adjusted outcomes of clinically-relevant postoperative fistula following pancreatoduodenectomy: a model for performance evaluation University of Pennsylvania   51 High performing whipple patients: factors associated with short length of stay after open pancreaticoduodenectomy Massachusetts General Hospital   52 The association between pancreatic fistula grade C and survival after pancreatic resection for pancreatic cancer Multicenter Group Study of Pancreatobiliary Surgery (Japan)   53 Does drain fluid amylase accurately predict pancreatic fistula? University of Wisconsin   54 Early drain removal: the middle ground between the drain versus no drain debate in patients undergoing pancreaticoduodenectomy. (ABSTRACT TRUNCATED)